🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF

RecruitingPhase 4Ages 50 Years - 80 YearsAllPotsawat Surabotsopon
NCT06367855 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Researchers are considering Dexamethasone as preemptive medication before minimally invasive spine fusion surgery to minimize postoperative back pain with minimal side effects, aiming to enhance the effectiveness of surgery and improve patient outcomes.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age range: 50-80 years old. * Undergoing MIS TLIF surgery at 1-2 spinal levels. Exclusion Criteria: * Previously undergone spine surgery. * HbA1C greater than or equal to 7.5 mg% * Allergic to all types of experimental medication. * History of using systemic steroids.
💊

What it tests

  • Dexamethasone
  • Normal saline
📍

Where

1 site
Thammasat university hospital
Pathum Thani, Thailand
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy